At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 8 enrolled
Drug / intervention
Rucaparib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With Metastatic Castration Resistant Prostate Cancer
In Brief
A Phase 1 clinical trial evaluating Rucaparib, Enzalutamide, and 1 other intervention for Metastatic Castration Resistant Prostate Cancer. Completed, enrolled 8 participants across 3 sites.
Detailed Summary
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination with Other Anticancer Agents in Patients with Metastatic Castration Resistant Prostate Cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartDec 2019
Primary CompletionNov 2021
Study CompletionJan 2023
TodayJul 2026
First PostedNov 27, 2019
Enrollment StartDec 5, 2019
Primary CompletionNov 25, 2021
Study CompletionJan 18, 2023
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 6.6 years ago
Interventions
Rucaparibdrug
Oral rucaparib will be administered twice daily
Enzalutamidedrug
Enzalutamide will be administered once daily. Enrollment into Arm A will be prioritized over Arm B until the objectives for Arm A have been achieved.
Abirateronedrug
Abiraterone will be administered once daily with prednisone